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The annual increase in depression worldwide together with an upward trend in the use of
alternative medicine as treatment asks for developing reliable safety profiles of herbal
based medicine. A considerable risk on adverse reactions exists when herbal remedies
are combined with prescription medication. Around 25% of the drugs, including many
antidepressants, depend on the activity of CYP2D6 for their metabolism and
corresponding efficacy. Therefore, probing CYP2D6 inhibition by the active substances
in herbal based medicine within the wild-type enzyme and clinically relevant allelic variants
is crucial to avoid toxicity issues. In this in silico study several compounds with herbal
origin suggested to have antidepressant activity were analyzed on their CYP2D6 wild-type
and CYP2D6*53 inhibition potential using molecular docking. In addition, several
pharmacokinetic properties were evaluated to assess their probability to cross the
blood brain barrier and subsequently reach sufficient brain bioavailability for the
modulation of central nervous system targets as well as characteristics which may hint
toward potential safety issues.
Keywords: CYP2D6 inhibition, natural products, molecular modeling, pharmacogenetics, adverse reactions,
antidepressants, drug safetyINTRODUCTION
Depression as a mood disorder has significantly increased (~18%) during the last decade affecting
over 300 million people as estimated by the World Health Organization (WHO) (Bashar et al.,
2019). Concurrently, an upward trend is seen in the use of antidepressants worldwide (Abbing-
Karahagopian et al., 2014; Forns et al., 2019; Iacobucci, 2019) in parallel with the use of
complementary and alternative medicine (CAM) (Kemper et al., 2013; Asher et al., 2017;
Kemppainen et al., 2018). A recent study reported that in Europe (21 surveyed countries) 30% of
the affected individuals used CAM to treat depression of which 10% included herbal medicine
(natural products) (Kemppainen et al., 2018). Antidepressants as neurotherapeutics must be able to
cross the blood-brain barrier (BBB) in order to modulate the function of the central nervous system
(CNS). The compound exchange between the blood and the nervous tissue is strictly controlled by a
continuous layer of endothelial cells which are kept together by tight junctions with a total estimated
surface of around 20 m2 (Wong et al., 2013). From a medicinal chemistry perspective,in.org May 2020 | Volume 11 | Article 6831
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weight, lipophilicity, hydrogen acceptor, and donor counts)
therefore need to fall within a narrower range compared to
regular drugs in order to be absorbed, dissolved and permeate
across the brain-barrier to reach the CNS (passive transport,
non-energy required). More hydrophilic modulators (or other
compounds) may still cross the barrier through carrier systems,
transporters, or endocytosis (active-transport, ATP required)
(Sanchez-Covarrubias et al., 2014; Vendel et al., 2019).
However, good BBB permeation does not guarantee that the
efficacious concentration of the compound in the CNS
compartment is reached (Dong, 2018). For the design of a
novel neurotherapeutically acting drug or natural-derived
compound, predicting its BBB permeability, partitioning, P450
cytochrome association (inhibitor/substrate/none) and off-target
binding in the early development stage is essential in order to
develop a compound that will have sufficient brain bioavailability
ensuring that the desirable therapeutic effect is acquired and
maintained at a concentration sufficient to modulate the CNS
system without inducing adverse reactions.
Safety profiles of antidepressant drugs are studied by many
groups and unfortunately are known to include also serious side
effects (Santarsieri and Schwartz, 2015; Carvalho et al., 2016;
Wang et al., 2018). The safety profiles of herbal medicine
products (from plant sources) are much less studied despite of
being frequently concomitantly administered with another
(synthetic) drug and bear a considerable risk for herbal-
induced toxicity issues (Ekor, 2014; Vahabi and Eatemadi,
2016; Singh and Zhao, 2017). Herbal-drug interactions (HDI)
can lead to harmful adverse events as they may alter the
pharmacokinetics (PK; adsorption, distribution, metabolism, or
excretion) and pharmacodynamics (PD; pharmacological effect
is changed in a synergetic, additive, or antagonistic way) profile
of the concomitantly administered drug (Hermann and
Richter, 2012).
The prediction of interactions of the natural compounds with
one major class of drug metabolizing enzymes, cytochromes
P450, especially the family member CYP2D6, is of particular
interest. This isoform is responsible for biotransformation of
about 25% of all the marketed drugs, and displays a very high
polymorphism rate (Zhou, 2009; Don and Smies ̌ko, 2018).
Inhibition or induction of CYP2D6 metabolism can alter the
pharmacokinetic profile of the concomitantly administered drug
and potentially can lead to toxicity or affect the drug efficacy
(Singh and Zhao, 2017). During the catalytic reaction,
interference of the substrate binding to the heme, the binding
of molecular oxygen, or the biotransformation step in which the
substrate is oxidized are prone to induce adverse reactions upon
inhibition (Correia Ortiz de Montellano, 2015). Based on these
three interference mechanisms, inhibitors can be divided
into three categories; i) reversible binders (competitive or
noncompetitive), ii) quasi-irreversible binders (also referred to
as suicide inhibitors) in which the inhibitors interact directly
with the heme-iron; iii) mechanism-based inhibitors, which
irreversibly bind to the protein and accelerate degradation or
oxidative fragmentation of the heme (Kalgutkar et al., 2007;Frontiers in Pharmacology | www.frontiersin.org 2Correia Ortiz de Montellano, 2015; Watanabe et al., 2016).
Compounds which inhibit the enzyme before the oxidative
events occur are usual ly reversible competit ive or
noncompetitive inhibitors. Mechanism-based or suicide
inhibitors more often act upon the oxygen transfer event or
subsequent to this step (Kalgutkar et al., 2007). The latter
category can have severe consequences; the complete
inactivation of the enzyme means that for several hours to
days the plasma concentrations of drugs which depend on the
enzyme activity to become metabolized will increase, which in
turn increases the risk on adverse reactions (Subehan et al.,
2006). Previous identified CYP2D6 mechanism-based inhibitor
drugs include paroxetine, 3,4-methylenedioxymethamphetamine
(MDMA), (1-[(2-ethyl-4-methyl-1H(-EMTPP-imidazol-5-yl)-
methyl]-4-[4-(trifluoromethyl)-2-pyridinyl]piperazine
(EMTPP), and 5-fluoro-2-[4-[(2-phenyl-1H-imidazol-5-yl)
methyl]-1-piperazinyl]pyrimidine (SCH66712) (Sridar et al.,
2002; Hollenberg et al., 2008; Livezey et al., 2012). Also
compounds from several natural sources such as St. John’s
wort, common sage, and goldenseal/berberine have been
identified to exercise a moderate to strong inhibition effect on
CYP2D6 wild-type (WT) and also on allelic variants (e.g.
CYP2D6*10) (Hellum and Nilsen, 2007; Gurley et al., 2008; Qu
et al., 2014). Hence there is an urgent need for cost- and time-
efficient methods which can help to determine the safety profile
not only of (new) drugs but also of natural compounds with
regard to their potential to inhibit CYP2D6 WT and clinically
relevant allelic variants. An advantageous combination of
methods used for identification of herbal compounds that
potentially inhibit CYP2D6 consists of an in silico approach for
a first fast screening, whereas resulting hits can be further verified
by experimental in vitro/in vivo studies (Hochleitner et al., 2017;
Vijayakumar et al., 2017). Recently, Hochleiter and co-workers
successfully demonstrated the potential and relevance of a
combined in silico–in vitro based workflow (including
pharmacophore screening and docking) to identify new
compounds derived from a natural source that inhibited
CYP2D6 WT (Hochleitner et al., 2017).
In this in silico study the safety profile of several compounds
from herbs which are known or suggested to have antidepressant
activity are assessed by: (i) determining their inhibitory effect on
CYP2D6 WT and the clinical relevant CYP2D6*53 (F120I,
A122S) allelic variant (Sakuyama et al., 2008) and (ii) assessing
their physiochemical properties along with several toxicity-
related descriptors in order to define their brain bioavailability
potential and off-target binding. The CYP2D6*53 allelic variant
has been only identified among the Japanese with an allele
frequency of 0.2% (Sakuyama et al., 2008). Moreover, it is the
only allelic variant associated with increased metabolism activity
(fourfold increase in CLint value) for the typical CYP2D6
substrate bufuralol. The increased activity is suggested to be
caused by the F120I mutation which is positioned close to the
heme. Therefore, investigating and comparing the docking poses
of theWT and CYP2D6*53 can provide insight regarding the role
of the F120I mutation. The safety profiles compiled for each
herbal compound will give a first indication if any toxicity issuesMay 2020 | Volume 11 | Article 683
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multidrug therapy. It has to be mentioned that the focus of this
study is on herbal compounds which are drug-like in terms of
size and physiochemical properties. The herbal compounds
which were not included in the analysis because they did not
comply with the library filtering criteria applied, might still be
suitable as antidepressant as they might cross the BBB and
modulate the CNS system using any of the active transport
mechanisms. However, evaluating their safety profile is much
more complex and this falls outside the scope of our study.MATERIALS AND METHODS
Compound Library Selection
The anti-depressant natural compound library was obtained
from ChemFaces (accessed July 2019), a high-purity natural
products manufacturer (Wuhan, P.R. China). The 3D
coordinate files were obtained from ChemSpider. For the 19
out of 51 compounds which passed filtering, a literature search
was performed using PubMed and Scopus to verify their
suggested antidepressant activity.
CYP2D6 Structure Selection
For the available co-crystalized structures [Protein Data bank
(PDB) IDs: 3QM4, 3TDA, 4WNT, 4WNU, 4WNV, 4WNW,
3TBG] it has been shown that the all-atom root-mean-square
deviation (RMSD) of the superimposed binding sites is lower
than 1 Å (Martiny et al., 2015). A major motivation of this study
is tohelp avoiding theCYP2D6 toxicitywithina co-therapy context,
hence competitive binding. At the moment, there is only one
protein-ligand complex structure available with a co-crystalized
substrate molecule: thioridazine (a typical antipsychotic drug, PDB
ID: 4WNW). Therefore, 4WNW was primarily used for docking
and the bindingmode analysis of the herbal compounds. However,
two additional structures (PDB IDs: 4WNT and 4WNU), co-
crystalized with the natural inhibitors ajmalicine and quinidine
respectively, were used as well in order to verify consensus of the
most favorably scored binding mode.
Library and Protein Preparation
The structures were processed using the standardized ligand
preparation procedure as implemented in the software LigPrep
(Schrödinger LLC.) The preparation procedure included bond
order assessment, tautomeric state, protonation evaluation (at
pH 7.4), and chemical structure consistency checks. For all the
compounds, the program MacroModel was used for the
minimization of the starting geometries. The three selected
CYP2D6 crystal structures (PDB IDs: 4WNW, 4WNU, and
4WNT, chain A) were retrieved from the PDB database and
processed using the Protein Preparation Wizard of Maestro
small-molecule drug discovery suite (v. 2017-2). Missing
residues and hydrogen atoms were added (at pH 7.4), bond
orders were assigned, and the co-crystalized ligand and co-
factors were removed. No crystal waters are resolved in
4WNW and the crystal waters in 4WNU and 4WNT wereFrontiers in Pharmacology | www.frontiersin.org 3deleted. Compound state I was modeled (Fe3+ bound to O2−,
zero-order bond). The distance between the iron and the oxygen
atoms was set to 1.97 Å. For the allelic variant CYP2D6*53 the
two residues of the wild type structure were mutated (F120I,
A122S) subsequently the mutated structure was fully minimized.
Toxicokinetic Parameters and Descriptor
Calculations
For each studied ligand, the QikProp program by Schrödinger
was used to calculate the Lipinski’s rule of 5 (hydrogen bond
donor and acceptor counts, molecular weight, logarithm of the
partition coefficient), Veber rules (polar surface area, number of
rotatable bonds), and several other absorption, distribution,
metabolism, and excretion (ADME) and toxicity related
descriptors offered by Schrödinger (logHERG, PCaco, logBB,
PMDCK, Human Oral Absorption, and CNS activity score). The
models behind the calculations assume absorption through
passive permeation. The descriptions can be found in
Table S6. Most psychoactive (CNS) drugs need to cross the
BBB for the modulation of a target neurotransmitter system (He
et al., 2018). Improved BBB permeation is usually obtained for
such drugs by following narrower Lipinski ranges compared to
other drugs (Pajouhesh and Lenz, 2005; Ghose et al., 2011). Two
prominent CNS studies which defined the pharmacokinetic
properties (including Lipinski’s rules) were used as filtering
guideline and an overview of them can be found in Table 1. In
addition, the online tool Molinspiration (www.molinspiration.
com/cgi-bin/properties) was used to assess structural similarity
and thus potential biological activity toward six important drug
classes (G-protein coupled receptor (GPCR) ligands, ion channel
modulators, kinase inhibitors, nuclear receptor ligands, protease
inhibitors, enzyme inhibitors).
Autodock Smina Docking
Smina, a fork of Autodock Vina (v.1.1.2) was used for docking.
Smina is focused on improving scoring and minimization and
includes several convenient functions which can be accessedTABLE 1 | Guidelines for the physicochemical properties associated with
improved blood-brain-barrier (BBB) penetration for central nervous system (CNS)
drug design.
Ghosea Pajouheshb Wagerc Lipinski
Descriptor min max (max) CNSd non-CNS
MW 141 452 <450 ≤360 (500) ≤400 <500
HbD 0 3 <3 ≤0.5 (3.5) ≤3 <5
HbA 1 8 <7 – ≤7 <10
logPo/w 0.16 6 <5 ≤3 (5) ≤5 <5
logS −0.4 0.5 – – – –
PSA 3.8 109 60 - 70 40 – 90 (120) – <140
rotB 0 8 <8 – – <10May 2020 | Volume 11 |abased on 317 approved CNS drugs, bbased on consensus of several studies discussed
in the paper, cderived from a set of 1500 drugs filtered from United States Adopted Names
(USAN) or International Nonproprietary names (INN) for good CNS penetration by Lipinski.
Descriptor meaning: MW, molecular weight; HbD, number of H-bond donors; HbA,
number of H-bond acceptors; logPo/w, logarithm of the oil/water partition coefficient; logS,
logarithm of the solubility coefficient; PSA, polar surface area of the molecule; rotB,
number of rotatable bonds in the molecule.Article 683
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based on one or several existing ligand(s) (Koes et al., 2013). The
prepared library and CYP2D6 prepared protein structures (WT
and CYP2D6*53) were used for the docking. The residues F112,
F120 (or I120 in the variant), E211, E215, E216, R221, Q244,
R296, I297, D301, S304, and F483 of CYP2D6 were defined as
flexible residues (side chains) during the docking. The random
seed number was set to 0 and an additional 8 Å buffer space was
added to the auto-generated box. All other settings were kept at
their default values.RESULTS
Pharmacokinetics Descriptor Based
Filtering
The ChemFaces antidepressant compound library contained
51 molecules for which all pharmacokinetic descriptors were
calculated using the program QikProp (Schrödinger LLC.).
Filtering criteria were based on pharmacokinetic property
guidelines specific for CNS therapeutic agents (Figure 1).
Earlier CNS pharmacokinetics analysis studies demonstrated
that CNS drugs fit within a smaller range (Table 1—Lipinski
non-CNS column) compared to the general Lipinski
guidelines (Table 1—Lipinski CNS column) (Pajouhesh and
Lenz, 2005).
Pajouhesh et al. provided guidelines for CNS drugs based on
the consensus of several studies discussed in their paper
(Pa jouhesh and Lenz , 2005) . Other CNS focused
physicochemical analyses found similar reference values with
some variation (Table 1). Ghose et al. calculated for 317 CNS and
627 non-CNS approved drugs the corresponding
physicochemical properties and the preferred ranges including
several pharmacokinetic descriptors using QikProp (Ghose et al.,
2011). Wager et al. analyzed 119 CNS drugs and 108 Pfizer CNS
candidates (Wager et al., 2010). An overview of all proposed CNS
guidelines can be found in Table 1. For filtering of the
compounds, the consensus values of Pajouhesh were applied as
guidelines. In addition, if one of the descriptors was lying outside
the guideline range, the other proposed ranges (Ghose or
Wagner, Table 1) were used to validate if the value was still
acceptable. Compounds with one violations of the Pajouhesh
guidelines are highlighted in Table 2. It must be mentioned that
the compounds which do not comply with the used filter criteriaFrontiers in Pharmacology | www.frontiersin.org 4might still be able to cross the BBB and modulate the CNS system
through an active transport.
After filtering, the remaining 19 compounds (Figure 2) were
docked in CYP2D6 WT and the CYP2D6*53 allelic variant for
the three prepared CYP2D6 structures (PDB IDs: 4WNW,
4WNU, and 4WNT) and several pharmacokinetic descriptors
were calculated. In addition, the literature was searched if any
evidence existed on CYP2D6 inhibition (Table S1), P450 (major)
isoformmetabolism (Table S2), and their ability to cross the BBB
(Table S3).
CYP2D6 Inhibition
CYP2D6 WT inhibition activity (varying from weak to potent
inhibition) data was found for seven compounds, four
compounds were identified to have no inhibition activity, and
for eight no data could be found (Table S1). Though the
neolignans honokiol and magnolol present in magnolia bark
extract have been considered to be safe in use by various
authorities (Sarrica et al., 2018), evidence exists on CYP2D6FIGURE 1 | The in silico safety profiling approach of the natural product antidepressant library.TABLE 2 | Pharmacokinetic properties of the natural antidepressants after
filtering for drug-like properties.
Compound MW HbD HbA logPo/w logS PSA rotB
(−)-Cytisine 190 1 5 0.7 −0.8 45 0
4-Hydroxyisoleucine 147 4 5 −2.5 0.0 91 5
5-Isopropyl-2 methylphenol 150 1 1 3.3 −2.3 21 2
Auraptenol 260 1 5 2.2 −2.6 61 5
Chelidonic acid 184 2 7 −0.6 −1.0 140 2
D-(−)-Synephrine 167 3 4 0.2 −0.3 58 5
Honokiol 266 2 2 5.0 −4.3 42 7
Isorhynchophylline 385 1 8 2.6 −4.0 85 4
L-Theanine 174 4 6 −3.0 0.2 111 6
Magnolol 266 2 2 5.0 −4.2 42 7
Naringenin 272 2 4 1.6 −3.4 100 3
Orcinol 124 2 2 0.8 0.1 45 2
Piperine 285 0 5 3.3 −3.5 48 5
Protopine 353 0 7 1.7 −1.1 60 0
Psoralidin 336 2 5 3.0 −5.0 92 4
Salvigenin 328 0 5 3.3 −4.1 77 4
Scopoletin 192 1 4 0.8 −1.7 71 2
Trans-methylisoeugenol 178 0 2 2.8 −3.7 16 3
Cannabidiol (CBC) 315 2 2 5.3 −6.0 39 7May 2020 | Volume 11 | ArticleThe bold highlighted compounds have one or two violation(s) of the Pajouhesh CNS
guidelines of which at least one is still within the acceptable regions guidelines of Ghose.
Descriptor meaning: MW, molecular weight; HbD, number of H-bond donors; HbA,
number of H-bond acceptors; logPo/w, logarithm of the oil/water partition coefficient; logS,
logarithm of the solubility coefficient; PSA, polar surface area of the molecule; rotB,
number of rotatable bonds in the molecule.683
Don and Smiesˇko CYP2D6 and Herbal Antidepressantsinhibition for magnolol (IC50 65.4 µM) (Zhang et al., 2019) and
weak inhibition for honokiol (Ki 12 µM) (Jeong et al., 2013).
Cannabidiol (CBD) one of the three major components in the
cannabis plant has been identified as potent atypical inhibitor
(IC50 6.52 µM) of CYP2D6 (Yamaori et al., 2011). Furthermore,
for piperine weak inhibition (IC50 3.2 µM) and protopine potent
competitive inhibition (Ki 78 nM) has been determined (Li et al.,
2011; Shamsi et al., 2017). Moderate CYP2D6WT inhibition was
f ound f o r (− ) - c y t i s i n e ( IC 5 0 2 8 . 9 µmo l / L ) and
isorhynchophylline (IC50 44.1 µmol/L) (Qu et al., 2014).
Literature search confirmed for 13 compounds that they are
able to cross the BBB (Table S3). Whether they reach a high
enough concentration to acquire and maintain their bioactivity
within the brain remains an open question and needs to be
confirmed by additional clinical studies. Experimental evidence
of CYP-mediated metabolism was found for nine of the
compounds, one has been assigned no CYP-metabolism
dependence, and for other nine no data was found (Table S2).
No literature was found that assigned CYP2D6 as major isoform
for metabolism for one of the compounds.Inhibition Binding Modes From Molecular
Docking
The top 10 binding poses were evaluated on potential CYP2D6
inhibition. The distance of the binding pose (distal or proximal)
between the heme and the ligand was evaluated as well as the
functional group and closest atom to the iron heme. If theFrontiers in Pharmacology | www.frontiersin.org 5distance between the heme-iron and any atom of the ligand
was below 6 Å it was assigned proximal binding, otherwise it was
assigned as distal. Several residues in the binding pocket are
essential for ligand binding. Glu216 and/or Asp301 are known to
act as first anchoring point by forming salt bridges with the
commonly protonated aliphatic nitrogen atom (at physical pH)
present in most typical CYP2D6 substrates. Subsequently Phe120
which resides in close proximity of the heme can further steer the
orientation of the ligand by interacting with the aromatic part of
the substrate through p-p stacking interactions (Rowland et al.,
2006; Wang et al., 2009; Wang et al., 2015). An example of
inhibition can be observed in the crystal CYP2D6 structure (PDB
ID: 4WNU) where quinidine (inhibitor) binds distal from the
heme and its protonated nitrogen forms electrostatic interactions
with both E216 and D301 (Wang et al., 2015). Based on this
knowledge docking binding modes were assigned to potentially
inhibit CYP2D6 if (i) a functional group (known not to be
normally metabolized) was interacting directly with the iron
heme and (ii) the distal binding from the heme prevented other
ligands to reach the heme and/or blocked interaction with D301
and/or E216. Furthermore, the binding profile of the pose was
evaluated on the presence of potential electrostatic interactions,
hydrogen bonding, and hydrophobic interactions. The docking
results can be found in Table 3 and a detailed overview of the
different interactions types of the best binding modes can be
found in Tables S4 and S5.
Within the top 10, the most productive pose(s) (based on the
mentioned criteria above) proximal and/or distal from the hemeFIGURE 2 | Overview of the selected natural compounds. The red asterisk indicates that previous research found CYP2D6 inhibition (potent to weak) activity for the
compound (see Table S1 for the reference), the red cross no CYP2D6 inhibition activity. For the remaining compounds no CYP2D6 inhibition data could be found.May 2020 | Volume 11 | Article 683
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that were binding (proximal and/or distal) can be found in the
supplementary data (Figures S1–S3). From the seven
compounds for which experimental evidence was found on
CYP2D6 WT inhibition activity, the binding poses of piperine,
protopine, honokiol, magnolol, and CBD were found to
potentially inhibit CYP2D6 WT and CYP2D6*53; the binding
mode of piperine in the WT was more strongly stabilized by
hydrophobic interactions with F120 than with I120 in
CYP2D6*53 (Figures 3 and 5B). Protopine formed mainly
electrostatic/hydrophobic interactions with the heme group. In
CYP2D6 WT p-p stacking was observed with F483 whereas a
hydrogen bond with Q244 was formed in CYP2D6*53 (Figure 3).
The binding modes observed (proximal and also distal) for
honokiol and magnolol in CYP2D6 WT and CYP2D6*53 were
such that one of the two ethylene tails pointed toward the heme
and one of the hydroxyl groups formed electrostatic interactions
with either D301 or a stabilizing hydrogen bond with S304
(Figure 4 and Figure S3). In addition, for CYP2D6 WT,
hydrophobic interactions with F120 and one of the phenyl
rings was observed.
For CBD, the best scored binding modes pointed the aliphatic
pentyl tail toward the heme and one of the two hydroxyl groups
was stabilized by either a hydrogen bond (S304, Q244) or
electrostatic interaction with D301 in CYP2D6 WT and
CYP2D6*53 (Figure S2). In CYP2D6 WT stabilizing
hydrophobic interactions between F120 and the aromatic ring
were found for honokiol and magnolol (Figure S3). For cytisine,
a binding pose pointing toward potential inhibition was only
observed in the CYP2D6WT; the protonated nitrogen of cytisine
formed an electrostatic interaction with D301. For
isorhynchophylline no reasonable binding poses that could
explain its inhibitory effect on CYP2D6 were generated.Frontiers in Pharmacology | www.frontiersin.org 6The compounds L-theanine, orcinol, naringenin, and
psoralidin for which experimental studies confirmed no
CYP2D6 WT inhibition (Figure 2, Table S1), docking results
did neither show any decisive inhibition binding modes in
CYP2D6 WT or CYP2D6*53. For the remaining eight
compounds for which no experimental CYP2D6 inhibition
data was found, 4-hydroxyisoleucine, chelidonic acid,
salvigenin, and trans-methylisoeugenol did not show any
CYP2D6 inhibition binding modes in both CYP2D6 WT or
CYP2D6*53. The proximal binding poses of thymol (5-
isopropyl-2-methylphenol) formed hydrophobic interactions
with F120 and hydrophobic/electrostatic interactions with the
heme group in CYP2D6 WT (Figure S1).
For the distal binding modes of (S)-auraptenol, the hydroxyl
group formed a hydrogen bond with S304 or/and also
electrostatic interactions with D301 or E216 in CYP2D6 WT
or CYP2D6*53 (Figure S1). In addition, p-p stacking between
the hydrophobic ring and F120 was observed for the highest
ranked pose in CYP2D6 WT. For D-(−)-synephrine proximal
binding was found in CYP2D6 WT with mainly electrostatic
stabilizing interactions (E216 and Q244) whereas proximal
binding in CYP2D6*53 with the protonated nitrogen formingTABLE 3 | Overview CYP2D6 WT and CYP2D6*53 docking results.
CYP2D6 wild-type CYP2D6*53
Compounds prox dis none prox dis none
(−)-Cytisine
4-Hydroxyisoleucine
5-Isopropyl-2-methylphenol
(S)-Auraptenol
Chelidonic acid
D-(−)-synephrine
Honokiol
Isorhynchopylline
L-theanine
Magnolol
Naringenin
Orcinol
Piperine
Protopine
Psoralidin
Salvigenin
Scopoletin
Trans-methylisoeugenol
Cannabidiol (CBD)The top 10 docking poses were evaluated on potential CYP2D6 inhibition by evaluating its
binding distance toward the heme (proximal or distal) together with its binding pocket
interaction profile.A
B
FIGURE 3 | CYP2D6 WT and CYP2D6*53 inhibition binding modes for (A)
piperine and (B) protopine. The best scored poses are shown docked into
4WNW (cyan), 4WNU (orange), and 4WNT (grey). To keep a clear overview,
only the interacting residues are displayed and labeled and solely the heme of
4WNW is displayed.May 2020 | Volume 11 | Article 683
Don and Smiesˇko CYP2D6 and Herbal Antidepressantselectrostatic interactions with D301 (Figure S2). Scopoletin
showed a similar proximal binding mode in which the oxygen
pointed in the direction of the heme group in both CYP2D6 WT
and CYP2D6*53 (Figure S2).
Pharmacokinetic and Toxicity-Related
Descriptors
Several pharmacokinetic descriptors calculated with QikProp
can be found in Tables 4 and 5. Chelidonic acid, L-theanine,
and naringenin have all a PSA above 100 Å, and 4-
hydroxyisoleucine and isorhynchophylline exceed the number
of acceptable hydrogen bond donors or acceptors for CNS drugs
which could decrease their ability to permeate the BBB (Table 2),
although experimentally evidence for all except chelidonic acid
exists that they cross the BBB (Table S3). From the toxicity-
related calculated QikProp descriptors (Table 4), eight
compounds have one or more value(s) lying outside the
recommended regions. 4-Hydroxyisoleucine, chelidonic acid,
and L-theanine have Pcaco and PMDCK predicted values
indicating potential issues with cell permeability, which is also
indicated by their predicted low human oral absorption and
inactive (below 0) CNS score. Naringenin and psoralidin are alsoFrontiers in Pharmacology | www.frontiersin.org 7predicted to be CNS inactive. CBD is a known inhibitor of the P-
glycoprotein, which substantially affects its bioavailability (Zhu
et al., 2006). Honokiol, magnolol, isorhynchophylline,
psoralidin, and salvigenin are predicted to interact with the
hERG channel. Furthermore, the online prediction platform
Molinspiration (www.molinspiration.com) was used for
prediction of a bioactivity score toward six of the most
important drug classes (GPCRs, ion channel modulators,
kinase inhibitors, nuclear receptor ligands, protease inhibitors,
enzyme inhibitors) based on the structure similarity with typical
class representatives (Table 5).
A bioactivity prediction score above 0 indicates a high
similarity to existing active compound. Considering the fact
that GPCRs are paramount for regulation of mood, pain,
cognition, and neurotransmitter release through synaptic
transmission, predicted bioactivity toward those receptors
would be expected for the modeled compounds (Huang and
Thathiah, 2015). Several CNS drugs (e.g. tricyclics such as
amitriptyline) modulate ion channel activity to reduce
depression in human (Kaczorowski et al., 2008; Lodge and Li,
2008) hence a bioactivity score for ion channel modulation above
0 would be considered as a positive result. For the remaining four
drug classes (kinase inhibitors, nuclear receptor ligands, protease
inhibitors, enzyme inhibitors) no similarity (activity) is desired.
Table 5 shows that cytisine, isorhynchophylline, naringenin,
protopine, and CBD are predicted to be similar (active) toward
the GPCR ligand and/or the ion channel modulator drug class.
Honokiol, naringenin, psoralidin, and CBD are predicted to be
similar (active) toward one of the four undesired drug classes.A
B
FIGURE 4 | CYP2D6 wild-type and CYP2D6*53 inhibition binding modes for
(A) Honokiol and (B) Magnolol. The best scored poses are shown docked
into 4WNW (cyan), 4WNU (orange) and 4WNT (grey). To keep a clear
overview, only the interacting residues are displayed and labeled and solely
the heme of 4WNW is displayed.TABLE 4 | QikProp calculated toxicity-related descriptors.
Compound logHERG PCaco
(nm/s)
logBB PMDCK
(nm/s)
HOA
(%)
CNS
(−)-Cytisine −3.8 491 0.4 254 79 1
4-Hydroxyisoleucine −1.5 15 −0.6 8 34 −1
5-Isopropyl-2-
methylphenol
−3.6 3697 0.1 2033 100 1
Auraptenol −4.0 1323 −0.5 669 96 0
Chelidonic acid 0.3 1 −1.8 1 26 −2
D-(−)-synephrine −4.8 193 −0.3 92 69 0
Honokiol −5.8 1615 −0.7 830 100 0
Isorhynchophylline −6.1 263 −0.3 129 86 1
L-theanine −1.0 6 −1.1 4 23 −2
Magnolol −5.7 1717 −0.6 887 100 0
Naringenin −5.0 130 −1.4 55 74 −2
Orcinol −3.3 912 −0.4 448 85 0
Piperine −4.8 3980 −0.1 2202 100 0
Protopine −4.4 1298 0.7 725 93 2
Psoralidin −5.7 312 −1.3 140 89 −2
Salvigenin −5.2 1504 −0.5 769 100 0
Scopoletin −3.8 627 −0.6 299 82 0
Trans-methylisoeugenol −3.9 9906 0.1 5899 100 1
Cannabidiol (CBD) −3.8 491 0.4 254 79 1May 2020 | Volume 11 | ArticlA detailed description of each descriptor can be found in Table S6.
Descriptor meaning: logHERG, predicted logarithm of the IC50 value for blockage of HERG
K+ channels; PCaco, predicted apparent Caco-2 cell permeability; logBB, predicted brain/
blood partition coefficient; PMDCK, predicted apparent MDCK cell permeability coefficient;
HOA, predicted human oral absorption on 0 to 100% scale; CNS, predicted central
nervous system activity on a –2 (inactive) to +2 (active) scale. Unfavorable scores are
highlighted in red. Bold font indicates compounds with problematic ADMET properties.e 683
Don and Smiesˇko CYP2D6 and Herbal AntidepressantsDISCUSSION
In this study the safety profile of 19 natural compounds was
evaluated on CYP2D6 inhibition using an in silico approach.
Inhibition was investigated for CYP2D6 WT and the allelic
variant CYP2D6*53 which is associated with increased
metabolism activity for bufuralol. The variant contains two
amino acid mutations (F120I, A122S) of which F120I is
positioned in close vicinity of the heme. Comparison of the
docking binding poses of the WT and variant can provide insight
on the function of the mutation in modulating the accessibility of
the compound to the heme. In addition, it may give an indication
regarding the impact of allelic variants with amino acid
mutations close to the heme on inducing inhibition. Moreover,
it is generally accepted that accurate site of metabolism
prediction requires to probe the accessibility and the reactivity
of the ligand atoms (Tyzack and Kirchmair, 2019). However, for
the aim of this study in which the focus is on inhibition, using a
time-efficient structure-based method such as docking to
investigate the compound-CYP interactions and subsequently
deduce its inhibition potential has previously shown to be a
valuable pre-screening strategy (Martiny et al., 2015, 6;
Hochleitner et al., 2017; Dutkiewicz and Mikstacka, 2018).
Subsequently, in vitro and in vivo safety studies can be
performed for examination of the smaller compound set. The
results from the natural compound docking correlated six out of
seven experimentally confirmed CYP2D6 WT inhibitors;
honokiol, magnolol, CBD, piperine, protopine, and cytisine. In
the allelic variant CYP2D6*53, potent inhibition binding modes
were observed as well except for cytisine. The docking poses of
(S)-auraptenol and scopoletin in CYP2D6 WT and CYP2D6*53
pointed toward potential inhibition activity as well. 5-Isopropyl-
2-methylphenol formed electrostatic interactions with theFrontiers in Pharmacology | www.frontiersin.org 8prosthetic heme group in CYP2D6 WT only. The mutation F120I
enabled for some compounds [especially D-(−)-synephrine,
scopoletin, (−)-cytisine] to get closer to the heme-oxygen. These
compounds have in common that they are relatively small and less
flexible, which restricts their possible binding modes to the heme-
oxygen compared to larger more flexible compounds such as for
example CBD or magnolol.
An interesting observation was made for the alkaloids piperine
and protopine both containing a methylenedioxyphenyl moiety
(Figure 5A). The highest scored docking pose of piperine and
protopine in both CYP2D6 WT and CYP2D6*53 positioned the
moiety in proximal vicinity of the heme (Figure 5B and Figure 3).
As described in the introduction, identification of mechanism-
based inhibitors (MBI) is particularly relevant considering the fact
that they bind irreversible and thus completely inactivate the
enzyme. Subsequently, during the time that the body needs to
produce new CYP2D6 enzymes which can take hours to days (e.g.
70 h in case of paroxetine) the plasma concentration of drugs which
require CYP2D6 activity for their biotransformation will increase
which in turn increases the chance on adverse reactions (Liston
et al., 2002). Previously identified CYP2D6 MBI drugs include
paroxetine and MDMA (3,4-methylenedioxymethamphetamine,
ecstasy) (Figure 3) (Sridar et al., 2002; Hollenberg et al., 2008;
Livezey et al., 2012). A common feature of the drugs is their
methylenedioxyphenyl moiety, which can be oxidized by
CYP2D6, forming a carbene intermediate. This intermediate
subsequently binds to the heme iron as an axial ligand. This
knowledge may explain the experimentally determined inhibition
activity of both natural compounds (Li et al., 2011; Shamsi et al.,
2017) and is in accordance with the observed binding modes.
However, the presence of the methylenedioxyphenyl can also lead
to reversible inhibition as shown in a recent study investigating
MDMA metabolism by CYP2D6 WT (Rodgers et al., 2018).TABLE 5 | Bioactivity prediction score for the 19 compounds toward six important drug classes.
Compound | Drug class GPCR ligand Ion channel
modulator
Kinase
inhibitor
Nuclear
receptor
ligand
Protease
inhibitor
Enzyme
inhibitor
(−)-Cytisine −0.58 0.39 −0.75 −1.1 −0.62 −0.25
4-Hydroxyisoleucine −0.72 −0.26 −1.31 −0.96 −0.71 −0.31
5-Isopropyl-2-methylphenol −1.02 −0.51 −1.15 −0.7 −1.25 −0.56
Auraptenol −0.24 −0.56 −0.73 0.14 −0.56 0.11
Chelidonic acid −1.05 −0.56 −0.93 −1.02 −0.92 −0.4
D-(−)-Synephrine −0.39 0.07 −0.79 −0.51 −0.88 −0.04
Honokiol 0.04 0.06 −0.08 0.32 −0.2 0.13
Isorhynchophylline 0.26 0.19 −0.3 0.03 −0.22 0.01
L-Theanine −0.53 −0.15 −1.15 −1.42 −0.08 −0.4
Magnolol −0.01 0.05 −0.15 0.2 −0.23 0.07
Naringenin 0.03 −0.2 −0.26 0.42 −0.12 0.21
Orcinol −2.26 −1.64 −2.35 −2.1 −2.59 −1.77
Piperine 0.15 −0.18 −0.13 −0.13 −0.1 0.04
Protopine 0.2 0.07 −0.35 −0.24 −0.07 0.17
Psoralidin −0.2 −0.09 −0.17 0.53 −0.15 0.21
Salvigenin −0.11 −0.27 0.15 0.13 −0.29 0.11
Scopoletin −1 −0.65 −0.95 −0.81 −1.16 −0.24
Trans-Methylisoeugenol −0.95 −0.53 −0.98 −0.72 −1.2 −0.53
Cannabidiol (CBD) 0.35 −0.14 −0.48 0.38 −0.19 0.33May 2020 | Volume 11 | AFavorable predicted scores are highlighted yellow, unfavorable red. Bold text indicates compounds with significant predicted bioactivities.rticle 683
Don and Smiesˇko CYP2D6 and Herbal AntidepressantsTherefore, a compound containing a methylenedioxyphenyl moiety
should be carefully investigated on CYP2D6 inhibition, depending
on the overall structure of the compound, the type of binding can be
reversible or irreversible.
The dynamic development of docking methods in recent
years and their wide application in structure-based design
projects especially in the pharmaceutical industry, the docking
binding modes are nowadays routinely employed to assess the
likelihood if a small molecule might bind at protein binding site
(Ferreira et al., 2015; Ballante, 2018; Śledź and Caflisch, 2018).
The accuracy of the poses and the estimation of the binding free
energy however depend directly on the protocol used and may
differ from target to target (Cournia et al., 2017; Mobley and
Gilson, 2017; Koukos et al., 2019). As cytochrome P450s are
known for their rather high flexibility our study used a flexible
docking protocol. All compounds could be successfully
accommodated within the binding site with reasonable binding
modes allowing interpretation of the structure-activity
relationships at both CYP2D6 WT and the CYP2D6*53 variant
(Figures 3 and 4). The stability of the predicted binding modes
can be further evaluated by replicated molecular dynamics (MD)
simulations. This would provide additional insight into the
dynamical stability of the intermolecular interactions identified
within the docked binding modes. Moreover, for the cases where
the binding is in close vicinity of the heme, the ultimate answer to
the question if an oxidation reaction may occur at a particular
ligand site can be derived from quantum mechanics/molecular
mechanics (QM/MM) calculations (Friesner and Guallar, 2005;
Olah et al., 2011; Reinhard and de Visser, 2017). However, both
MD and QM/MM simulations belong to the most CPU-intensive
approaches and are not practicable for our rather large set
of compounds.Frontiers in Pharmacology | www.frontiersin.org 9In silico evaluation of toxico/pharmacokinetic descriptors
(Table 4) demonstrated that the herbal origin studied
compounds generally fulfill all criteria needed for absorption
from the gastrointestinal tract after oral intake. Most descriptor
values fit also into the narrower range defined for CNS active
drugs. Chelidonic acid, L-theanine, and naringenin feature
slightly higher PSA values when calculated using 3D approach
(QikProp), but cannot be directly disqualified as unpermeable;
2D based algorithms generate values closer to the upper
threshold value for the CNS availability (Shityakov et al.,
2013). Moreover, the PSA descriptor bears the risk of
overinterpretation. For instance a hydroxyl (OH) group is
more expensive to desolvate and transfer through the
membrane than a carbonyl oxygen (=O), while they both
contribute to the PSA with very similar fraction (20 Å vs. 17
Å2). Small deviations in one descriptor should not translate to
complete loss of bioavailability. In fact, sufficient oral availability
(> 69%) was confirmed using specialized predictive models of
QikProp for 16 compounds, with remaining three being at least
partially absorbed (23%–34%). Estimated permeation
coefficients in the Caco-2 cells follow this trend. The two
compounds, 4-hydroxyisoleucine and L-theanine, predicted to
have low permeation coefficients, have an amino acid character
and are therefore likely using an active transport mechanism
(Smith, 2000). Descriptor values calculated using specialized
modules for the CNS activity and BBB permeation showed
positive scores for six compounds, eight were scored neutral
and five had negative scores. Lower scores than expected for CNS
active compounds might be caused by the fact that QikProp
modules were trained using drug molecules, which are typically
located in different region of the chemical space than natural
compounds (Ioakimidis et al., 2008). The same applies forA B
FIGURE 5 | Mechanism based CYP2D6 inhibition. (A) Piperine and protopine both contain a methylenedioxyphenyl moiety which has been associated with
mechanism-based inhibition (MBI) of CYP2D6 (e.g. paroxetine and MDMA are CYP2D6 MBI). (B) The best scored binding mode (in 2D) for each is shown in
CYP2D6 WT and CYP2D6*53. The asterisk indicates the atom closest to the heme-iron. Color code: hydrophobic interactions; brown, electrostatics; purple, and
hydrogen bonds; blue.May 2020 | Volume 11 | Article 683
Don and Smiesˇko CYP2D6 and Herbal Antidepressantssimilarity based indices generated by the Molinspiration
Bioactivity Predictor, which is also build on typical drug-like
molecules falling into respective categories. Nevertheless, it is
interesting to see that the studied compounds show similarity
with different compound groups, that might be associated
to their desired (antidepressant), but also undesired
pharmacological effects (endocrine disruption, cardiotoxicity).CONCLUSIONS
Natural remedies are often associated with a safe use. Buying
herbal supplements seems to be harmless as most of the time no
special warnings can be found in the accompanying information.
However, an increasing trend of using natural compounds as
single antidepressant or in polypharmacy needs to be handled
with caution. Toxicity issues may arise depending on the dose
and therapy and its P450 metabolism dependence if the herbal
compound or a complex product is not given safety clearance by
the FDA or another established authority. CYP2D6 inhibition or
off-target binding are particularly dangerous. The in silico results
of this study indicate for several of the natural compounds
suggested to be used as antidepressant that a potential
increased risk may exist on adverse reactions triggered by
CYP2D6 inhibition or another off-target analyzed (kinase
inhibitors, nuclear receptor ligands, protease inhibitors,
enzyme inhibitors, hERG binding). From the 19 natural
compounds analyzed, nine indicated no CYP2D6 inhibition for
both CYP2D6 WT and CYP2D6*53 (4-hydroxyisoleucine,
chelidonic acid, isorhynchopylline, L-theanine, naringenin,
orcinol, psoralidin, salvigenin, trans-methylisoeugenol). TheFrontiers in Pharmacology | www.frontiersin.org 10other 10 natural compounds ((−)-cytisine, 5-isopropyl-2-
methylphenol, s-auraptenol, D-(−)-synephrine, honokiol,
magnolol, piperine, protopine, scopoletin and CBD) showed
clearly potential for CYP2D6 WT and/or CYP2D6*53
inhibition. If administered with a concomitant drug which
depends on CYP2D6 activity this may lead to adverse
reactions. Further experimental investigations are required to
confirm the outcome of the in silico docking, the off-target
predictions and the toxicity descriptors. Especially hERG
binding should be evaluated for honokiol, magnolol,
isorhynchopylline, psoralidin, and salvigenin.DATA AVAILABILITY STATEMENT
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